niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

That includes GlaxoSmithKline’s (GSK) Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).

FDA accepts review to broaden GSK’s Zejula label

GSK is seeking approval for Zejula (niraparib) as a first-line maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of biomarker status.
GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK took full ownership of the therapy in 2018. GSK’s push into cancer has also included its $5.1bn acquisition of Tesaro, which brought in PARP inhibitor Zejula (niraparib).
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

The filing means that Rubraca has beaten rivals such as AstraZeneca/Merck &Co’s market-leading Lynparza (olaparib), GlaxoSmithKline/Janssen’s Zejula (niraparib) and Pfizer’s new entrant Talzenna (talazoparib) to
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

If the FDA backs the new indication it will help AZ and Merck to maintain their lead over newer rivals in the PARP inhibitor class, including GlaxoSmithKline’s Zejula (niraparib), Clovis
GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

GSK will also increase prices on around 30 of its drugs, including its Ellipta inhaler, its cancer drug Zejula (niraparib) and HIV products from its ViiV division.

More from news
Approximately 4 fully matching, plus 40 partially matching documents found.

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Add my company

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....